Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Eide

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Leukemia|June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSusan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Haematologica|December 30, 2017
A novel <i>AGGF1-PDGFRb</i> fusion in pediatric T-cell acute lymphoblastic leukemiaMatthew S Zabriskie, Orlando Antelope, Anupam R Verma, et al.
Cancer Research|April 12, 2013
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosisThomas O'Hare, Christopher A Eide, Anupriya Agarwal, et al.
Blood Cancer Discovery|September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Blood|February 7, 2008
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemiaMarc M Loriaux, Ross L Levine, Jeffrey W Tyner, et al.
The New England Journal of Medicine|May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLJulia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2024
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid LeukemiaRucha V Modak, Katia G de Oliveira Rebola, John McClatchy, et al.
Cell Death & Disease|February 24, 2018
Metformin exerts multitarget antileukemia activity in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasmsJoão Agostinho Machado-Neto, Bruna Alves Fenerich, Renata Scopim-Ribeiro, et al.
Blood|December 11, 2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsJamshid S Khorashad, Todd W Kelley, Philippe Szankasi, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Leukemia|June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSusan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Haematologica|December 30, 2017
A novel <i>AGGF1-PDGFRb</i> fusion in pediatric T-cell acute lymphoblastic leukemiaMatthew S Zabriskie, Orlando Antelope, Anupam R Verma, et al.
Cancer Research|April 12, 2013
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosisThomas O'Hare, Christopher A Eide, Anupriya Agarwal, et al.
Blood Cancer Discovery|September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Blood|February 7, 2008
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemiaMarc M Loriaux, Ross L Levine, Jeffrey W Tyner, et al.
The New England Journal of Medicine|May 10, 2013
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CMLJulia E Maxson, Jason Gotlib, Daniel A Pollyea, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2024
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid LeukemiaRucha V Modak, Katia G de Oliveira Rebola, John McClatchy, et al.
Cell Death & Disease|February 24, 2018
Metformin exerts multitarget antileukemia activity in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasmsJoão Agostinho Machado-Neto, Bruna Alves Fenerich, Renata Scopim-Ribeiro, et al.
Blood|December 11, 2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsJamshid S Khorashad, Todd W Kelley, Philippe Szankasi, et al.
Pageof 9